Binyu Shi, Xinyuan Zhou, Junjun Zhou, Gang Huang, Jianjun Liu, Jin Zhang, Weijun Wei
{"title":"cd70靶向放射治疗：现在与未来。","authors":"Binyu Shi, Xinyuan Zhou, Junjun Zhou, Gang Huang, Jianjun Liu, Jin Zhang, Weijun Wei","doi":"10.1053/j.semnuclmed.2025.08.001","DOIUrl":null,"url":null,"abstract":"<p><p>The cluster of differentiation 70 (CD70), a transmembrane glycoprotein encoded by TNFSF7, is a member of the tumor necrosis factor (TNF) superfamily and serves as the ligand for the co-stimulatory receptor CD27. It is aberrantly overexpressed in various malignancies, including clear cell renal cell carcinoma (ccRCC) and nasopharyngeal carcinoma (NPC). Although CD70-directed radiotheranostics may address key challenges faced by antibody-drug conjugates (ADCs) and chimeric antigen receptor T (CAR-T) therapies, such as drug resistance and tumor penetration barriers, this therapeutic approach remains unexplored in clinical settings. In this review, we highlight the expression of CD70 in normal tissues and organs, as well as in different tumor types, presenting promising results from CD70-targeted immuno-PET/CT imaging in recent clinical trials. Furthermore, we emphasize relevant therapeutic radiopharmaceuticals currently in preclinical or clinical trials, providing a rational roadmap for guiding future development of CD70-targeted radiotheranostics.</p>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":" ","pages":""},"PeriodicalIF":5.9000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CD70-Targeted Radiotheranostics: Now and Future.\",\"authors\":\"Binyu Shi, Xinyuan Zhou, Junjun Zhou, Gang Huang, Jianjun Liu, Jin Zhang, Weijun Wei\",\"doi\":\"10.1053/j.semnuclmed.2025.08.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The cluster of differentiation 70 (CD70), a transmembrane glycoprotein encoded by TNFSF7, is a member of the tumor necrosis factor (TNF) superfamily and serves as the ligand for the co-stimulatory receptor CD27. It is aberrantly overexpressed in various malignancies, including clear cell renal cell carcinoma (ccRCC) and nasopharyngeal carcinoma (NPC). Although CD70-directed radiotheranostics may address key challenges faced by antibody-drug conjugates (ADCs) and chimeric antigen receptor T (CAR-T) therapies, such as drug resistance and tumor penetration barriers, this therapeutic approach remains unexplored in clinical settings. In this review, we highlight the expression of CD70 in normal tissues and organs, as well as in different tumor types, presenting promising results from CD70-targeted immuno-PET/CT imaging in recent clinical trials. Furthermore, we emphasize relevant therapeutic radiopharmaceuticals currently in preclinical or clinical trials, providing a rational roadmap for guiding future development of CD70-targeted radiotheranostics.</p>\",\"PeriodicalId\":21643,\"journal\":{\"name\":\"Seminars in nuclear medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.9000,\"publicationDate\":\"2025-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in nuclear medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1053/j.semnuclmed.2025.08.001\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1053/j.semnuclmed.2025.08.001","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
The cluster of differentiation 70 (CD70), a transmembrane glycoprotein encoded by TNFSF7, is a member of the tumor necrosis factor (TNF) superfamily and serves as the ligand for the co-stimulatory receptor CD27. It is aberrantly overexpressed in various malignancies, including clear cell renal cell carcinoma (ccRCC) and nasopharyngeal carcinoma (NPC). Although CD70-directed radiotheranostics may address key challenges faced by antibody-drug conjugates (ADCs) and chimeric antigen receptor T (CAR-T) therapies, such as drug resistance and tumor penetration barriers, this therapeutic approach remains unexplored in clinical settings. In this review, we highlight the expression of CD70 in normal tissues and organs, as well as in different tumor types, presenting promising results from CD70-targeted immuno-PET/CT imaging in recent clinical trials. Furthermore, we emphasize relevant therapeutic radiopharmaceuticals currently in preclinical or clinical trials, providing a rational roadmap for guiding future development of CD70-targeted radiotheranostics.
期刊介绍：
Seminars in Nuclear Medicine is the leading review journal in nuclear medicine. Each issue brings you expert reviews and commentary on a single topic as selected by the Editors. The journal contains extensive coverage of the field of nuclear medicine, including PET, SPECT, and other molecular imaging studies, and related imaging studies. Full-color illustrations are used throughout to highlight important findings. Seminars is included in PubMed/Medline, Thomson/ISI, and other major scientific indexes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
